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Abstract
Sodium and fluid retention is a hallmark and a therapeutic challenge of the
nephrotic syndrome (NS). Studies support the “overfill” theory of NS with
pathophysiological proteolytic activation of the epithelial sodium channel
(ENaC) which explains the common observation of suppressed renin –an-
giotensin system and poor therapeutic response to ACE inhibitors. Blockade
of ENaC by the diuretic amiloride would be a rational intervention compared
to the traditionally used loop diuretics. We describe a 38-year-old male
patient with type1 diabetes who developed severe hypertension (200/
140 mmHg), progressive edema (of at least 10 L), and overt proteinuria
(18.5 g/24 h), despite combined administration of five antihypertensive drugs.
Addition of amiloride (5 mg/day) to treatment resulted in resolution of
edema, weight loss of 7 kg, reduction in blood pressure (150/100–125/
81 mmHg), increased 24 h urinary sodium excretion (127–165 mmol/day),
decreased eGFR (41–29 mL/min), and increased plasma potassium concentra-
tion (4.6–7.8 mmol/L). Blocking of ENaC mobilizes nephrotic edema and
lowers blood pressure in NS. However, acute kidney injury and dangerous
hyperkalemia is a potential risk if amiloride is added to multiple other antihy-
pertensive medications as ACEi and spironolactone. The findings support that
ENaC is active in NS and is a relevant target in adult NS patients.
Introduction
Generalized edema is an essential clinical feature of NS inde-
pendent of various underlying etiologies. Two major
hypotheses have been proposed to explain edema formation,
the underfill and overfill theory, respectively, which have been
recently reviewed (Ellis 2015; Hoorn and Ellison 2017; Ray
et al. 2015; Teoh et al. 2015). In brief, according to the un-
derfill theory, the loss of albumin from plasma to the urine
leads to reduced plasma oncotic pressure and escape of fluid
to the interstitial compartment. The secondary activation of
the renin–angiotensin–aldosterone system (RAAS) triggers
renal sodium and fluid retention to preserve blood pressure
and intravascular volume (Brown et al. 1982b; Oliver and
Owings 1960; Usberti et al. 1995; Van de Walle et al. 1996).
Data showed that RAAS is not activated in most patients
with NS (Brown et al. 1982a; Meltzer et al. 1979); that vol-
ume correction with albumin substitution does not resolve
edema nor enhances natriuresis (Geers et al. 1984; Koomans
et al. 1984) and that RAAS blockade and adrenalectomy (in
animals) does not resolve edema (Brown et al. 1984; de
Seigneux et al. 2006). The overfill theory is based on a
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primarily impaired Na+ excretion in NS kidneys (Ichikawa
et al. 1983), recapitulated in isolated ex vivo perfused
nephrotic kidney. Impaired sodium excretion explains the
common coincident suppression of renin and aldosterone in
NS and is associated with attenuated effectiveness of, for
example, loop diuretics. In agreement, the site of sodium
retention along the nephron in NS is after the distal convo-
luted tubule (Ichikawa et al. 1983). In rat, nephrotic syn-
drome-mediated Na+ retention was ameliorated by
amiloride (Deschenes et al. 2001; Feraille et al. 1993; Lourdel
et al. 2005; Svenningsen et al. 2009). Thus, ENaC has been
proposed as the culprit in NS although at tissue level ENaC
protein abundance and membrane association is not chan-
ged dramatically. ENaC has a key role in regulation of the
extracellular fluid volume and blood pressure, but besides
activation by regulatory hormones, specific proteases can
activate the channel (Kleyman et al. 2009; Orce et al. 1980;
Passero et al. 2008; Vallet et al. 1997). Proteinuria is associ-
ated with urinary serine protease activity primarily due to
aberrant filtration of these proteases across a damaged
glomerular filtration barrier (Schork et al. 2016; Svenningsen
et al. 2009, 2012). Volume retention in NS was prevented by
a protease inhibitor (Bohnert et al. 2017). Nephrotic urine
activates amiloride-sensitive current in collecting duct cells.
Thus, the overfill mechanism is based on proteolytically acti-
vated hyperactive ENaC channels as reviewed by Ray et al.
(2015).
The diuretic strategy to manage fluid retention in NS is
a therapeutic challenge. Loop diuretics are traditionally the
drug of choice, with incremental dosing, guided by body
weight, GFR, and degree of edema. If this treatment fails to
reduce edema, combination with a thiazide diuretic is usu-
ally attempted. If insufficient, other strategies have been
proposed, for example, intravenous administration of loop
diuretics with continuous infusion or in cases of extreme
generalized edema or compromised cardiorespiratory func-
tion, addition of intravenous human-albumin or dialysis
(Davison et al. 1974; Fliser et al. 1999; Haws and Baum
1993; Weiss et al. 1984). On the other hand, data have
clearly shown that loop diuretics are less potent in NS com-
pared to healthy controls (Danielsen et al. 1985; Jespersen
et al. 1991) however, active ENaC, which is localized
downstream loop diuretic-sensitive transporters would
counteract the effect. At current state of knowledge, data
are accumulating to suggest that ENaC blockade with, for
example, amiloride is a rational approach to reduce edema
and weight in NS based on mechanistic insight (Deschenes
et al. 2004; Doucet et al. 2007; Hoorn and Ellison 2017).
Two early and empirical attempts to treat nephrotic syn-
drome with triamterene indicated a beneficial effect on
edema (Campanacci et al. 1963; Cavazzuti 1965). A small
intervention study showed that amiloride significantly
increased natriuresis and reduced weight in nephrotic
pediatric patients (Deschenes et al. 2004). No controlled
clinical trials in nephrotic patients have been performed,
although treatment with amiloride in other conditions with
proteinuria have been tested (Andersen et al. 2016; Oxlund
et al. 2014; Unruh et al. 2017).
Case Presentation
A 38-year-old male was referred to the outpatient clinic at
the Department of Nephrology with treatment-resistant
hypertension, rapidly developing edema and overt protein-
uria (week 11, Fig. 1A). The patient was initially followed at
the outpatient clinic at the Department of Endocrinology
with poorly controlled type 1 diabetes for 15 years with
microvascular complications including retinopathy and albu-
minuria, thus presenting with urinary albumin/creatinine
ratios over 1000 mg/g for at least 3 years. There were no
clinical signs of neuropathy. Plasma creatinine had previ-
ously been normal, in the range 60–90 lmol/L. Through sev-
eral years, the patient had hypertension that was well-
controlled with ACE inhibitors. One year prior to the presen-
tation, blood pressure increased progressively concomitant
with development of edema. The patient presented with sev-
ere hypertension (200/140 mmHg, week 0, Fig. 1B), edema
and urinary protein excretion at 18.5 g/24 h (week 1,
Fig. 1D). Despite increasing doses and numbers of antihy-
pertensive agents and diuretics (Fig. 1A), blood pressure
continued to be severely elevated combined with progressive
fluid overload and proteinuria (Fig. 1B and D). The patient
was referred to the Department of Nephrology (week 11,
Fig. 1A–D) with NS. At this time, a renography performed
on treatment with an ARB revealed no perfusion of the right
kidney, and ultrasound confirmed the presence of a 4 cm
long, hypoechoic structure in the right retroperitoneal space
believed to be a rudimentary right kidney. The left kidney
was morphologically and scintigraphically normal. The anti-
hypertensive medication at referral was thiazide, beta-
blocker, calcium channel antagonist, ACE-inhibitor and
mineralocorticoid receptor antagonist spironolactone with
no suspicion of noncompliance (Fig. 1A). At presentation,
the patient was alert but complained of headache, fatigue,
and recent weight gain of 10 kg. On physical examination,
blood pressure was 161/102 mmHg, and the patient revealed
periorbital and universal pitting edema, no signs of ascites
and otherwise normal examination. Based on edema, pro-
teinuria, and hypoalbuminemia (25 g/L), he was diagnosed
with NS assumed to be related to diabetes. There was nega-
tive test for M-component and no detectable autoantibodies
(ANA, ANCA, anti-GBA) nor phospholipase A2 antibody.
Hepatitis B and C as well as HIV serology were negative. To
reduce blood pressure, treatment with a loop diuretic was
initiated (furosemide 80 mg/day, Fig. 1A). After 2 weeks
without effect on edema and blood pressure (Fig. 1B and D),
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with a decrease in eGFR and no change in plasma potassium
(Fig. 1C), furosemide was stepped up to 160 mg/day
(Fig. 1A). Despite treatment with five combined antihyper-
tensive/diuretic agents, there was only a minor weight loss
(~1 kg) and reduction in blood pressure. Therefore, a low
dose of the ENaC blocker amiloride 5 mg/day was initiated
(Fig. 1A) and a 7-day follow-up was scheduled, which the
patient missed. At next contact after 2 weeks, this treatment
resulted in effective resolution of edema, concomitant weight
loss of 7 kg and reduction in blood pressure from 150/
100 mmHg to 125/81 mmHg (Fig. 1B). The patient contin-
ued his normal diet and 24 h urinary sodium excretion
increased from 127 mmol/day to 165 mmol/day. Proteinuria
decreased from 8 g/day to 4.1 g/day (Fig. 1D), eGFR
decreased from 41 mL/min to 29 mL/min and plasma potas-
sium concentration increased from 4.6 to 7.8 mmol/L
(Fig. 1C). The patient was immediately hospitalized for car-
diac monitoring and treatment of hyperkalemia. Amiloride
and spironolactone were both discontinued. At follow-up
5 weeks later, a combination-drug containing 2.5 mg
amiloride and 25 mg hydrochlorthiazide was successfully
reinitiated due to increased blood pressure 141/96 and
edema. At the last visit to the outpatient clinic, the patient
received the following antihypertensive /diuretic drugs;
amiloride/hydrochlorthiazide 2.5 + 25 mg/day, metoprolol
50 mg/day, furosemide 125 mg/day, lercanidipine 10 mg/
day, and lisinopril 20 mg/day and his blood pressure was
112/80, body weight was stable at 90 kg (15 kg weight loss),
plasma potassium was 4.6 mmol/L, and plasma creatinine
was 203 lmol/L with eGFR at 35 mL/min.
Discussion
The present case illustrates two points; (I) hypertension
and edema in NS depends critically on ENaC activity,
and (II) when treatment directed at inhibiting aldos-
terone/ENaC is added on top of other antihypertensives,
even with intact kidney function, this involves a serious
hazard for hyperkalemia and a decline in kidney function
likely related to the abrupt decrease in blood pressure.
The strategy to overcome volume expansion and hyper-
tension in this patient was initially to increase the doses
of antihypertensive medication including thiazide/loop
diuretic combination. Despite titrating antihypertensives
to include five different drugs and notably with high
doses of loop diuretics, there was only a very modest
reduction in blood pressure and no significant effect on
edema. Despite ACE-inhibition and aldosterone blockade,
the powerful action of low-dose amiloride showed that
unopposed ENaC-mediated Na+ transport in the distal
nephron (connecting tubules and connecting ducts) is
sufficient to compensate for the action of “upstream”
loop and thiazide diuretics. Thus the “diuretic resistance”
associated with NS is not absolute and could be related to
active ENaC. This is in agreement with mouse studies
with segmental knock out of ENaC (Perrier et al. 2016)
and it is also in agreement with the powerful therapeutic
action of systematic, segment-specific combined diuretics
to combat resistant hypertension in patients (Bobrie et al.
2012). The number of ENaC channels expressed at the
cell surface is regulated by aldosterone (Masilamani et al.
1999) and the open probability is transitioned to a highly
active state by extracellular serine proteases (Caldwell
et al. 2005, 2004; Vallet et al. 1997) as recently reviewed
(Kleyman et al. 2018). Thus, although MR antagonist
would suppress the ENaC abundance in the present
patient, these constitutively expressed membrane-asso-
ciated channels are likely activated abnormally through
proteolysis (Caldwell et al. 2005; Passero et al. 2008; Patel
et al. 2012; Picard et al. 2008; Svenningsen et al. 2009).
This could explain the sensitivity to amiloride despite
spironolactone and ACEi. Amiloride is freely filtered and
mainly secreted to the tubular fluid where concentrations
10-20 lmol/L are achieved (Andersen et al. 2016). Besides
blocking ENaC, amiloride inhibits luminal urokinase-type
plasminogen activator (uPA) (Oxlund et al. 2014; Staehr
et al. 2015; Vassalli and Belin 1987), a zymogen that con-
verts filtered plasminogen to active plasmin. This may
have contributed to the potent natriuretic action,
although other serine proteases in the urine may still be
active (Svenningsen et al. 2015).
Despite initial dual blockade of RAAS with ACE inhibi-
tors and spironolactone, hyperkalemia did not develop
until supplementation with amiloride. This indicates that
hyperkalemia was not the result of RAAS inhibition, but
rather a result of blocking ENaC. In the current case,
hyperkalemia was likely aggravated by the decrease in kid-
ney function which also could explain the reduction in
proteinuria. The decline in eGFR was reversible. It could
be speculated that the prompt drop in blood pressure in
a patient with possible impairment of the autoregulation
of renal blood flow combined with a rapid loss of esti-
mated 7L of extracellular fluid might have worsened kid-
ney function. Acute kidney injury and hyperkalemia have
previously been reported in a controlled clinical trial in
proteinuric patients given amiloride, and the trial was
stopped early (Unruh et al. 2017). Thus, the present case
and previous studies emphasize the risk of serious adverse
effects. This underlines the need to consider exchanging
antihypertensives; to monitor potassium concentration
and follow blood pressure carefully when initiating
amiloride treatment in NS patients who appear highly
sensitive. Furthermore, patients should be informed to
adhere to low potassium diets and potentially it could be
necessary to add a potassium-binding resin to mitigate
the risk of hyperkalemia.
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In summary, the present case shows that the addition
of the ENaC blocker amiloride to multidrug regimen
reduces edema, body weight, and blood pressure in a sev-
ere NS case. It also illustrates that careful monitoring and
stepwise titration is necessary to minimize the risk for
acute injury and hyperkalemia.
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